Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
May 04, 2017
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes
May 02, 2017
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
REDWOOD CITY, Calif. , May 2, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results.  The call and webcast will follow the
Mar 29, 2017
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
Designated One of the 'Best Posters' by EAU, Results Highlight Expanded Value of Genomic Prostate Score™ in Assessing Risk and Long-term Outcomes in Patients Across Stages of Disease
Mar 24, 2017
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence Score® Results
Mar 20, 2017
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test
Feb 28, 2017
Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the Cowen and Company 37 th Annual Health Care Conference at the Marriot Copley Place in Boston
Feb 16, 2017
Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection
Presentations at 2017 ASCO Genitourinary Cancers Symposium in Orlando, Feb. 16-18, Underscore Test's Clinical Utility in Low- and Intermediate-risk Patients
Feb 14, 2017
Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
Achieved Profit in the Fourth Quarter of 2016; Guides to Full Year Profit in 2017
Delivered 14 Percent Revenue Growth and 11 Percent Test Growth in 2016
Generated $3.6M Prostate Revenue and Increased Prostate Test Volume by 29 Percent in the Fourth Quarter
Conference Call Today at 4:30 p.m. ET
Feb 07, 2017
Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017
REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and
Jan 03, 2017
Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Jan. 3, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 35 th Annual J.P. Morgan Healthcare Conference at the Westin St.